Lisata Therapeutics, Inc. filed a Form 8-K/A (Amendment No. 1) on November 12, 2026, amending its September 17, 2026 Current Report to add audited and unaudited financial statements of acquired company Marea Therapeutics, Inc. and related pro forma financial information.

Key Highlights

  • Acquisition reported: The original filing reported the completion of the acquisition of Marea Therapeutics, Inc., a Delaware corporation, on September 17, 2026.
  • Audited financials added: Ernst & Young LLP audited the combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the years ended December 31, 2025 and 2024.
  • Unaudited interim statements included: Condensed combined interim financial statements cover the period as of June 30, 2026 and December 31, 2025, and for the six months ended June 30, 2026 and 2025.
  • Pro forma information provided: Unaudited pro forma combined interim financial information covers the six months ended June 30, 2026 and the year ended December 31, 2025.
  • Signed by CEO: The amendment was signed by David J. Mazzo, Ph.D., Chief Executive Officer, on November 12, 2026.

Lisata Therapeutics Supplements Marea Acquisition Report With Required Financial Exhibits

Lisata Therapeutics, Inc. (NASDAQ:LSTA), a Delaware corporation headquartered in Liberty Corner, NJ, filed this Amendment No. 1 on Form 8-K/A to supplement its original Current Report on Form 8-K, which was filed on September 17, 2026 and reported, according to the filing, "the completion of the acquisition of Marea Therapeutics, Inc., a Delaware corporation." The amendment updates Item 9.01 of the original report to include financial disclosures required following the acquisition.

According to the filing, the amendment serves two purposes: first, to include the audited combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the years ended December 31, 2025 and 2024, which were audited by Ernst & Young LLP, Marea's independent auditors, and attached as Exhibit 99.3; and second, to include unaudited condensed combined interim financial statements for the same entities as of June 30, 2026 and December 31, 2025, and for the six months ended June 30, 2026 and 2025, attached as Exhibit 99.4.

The filing also attaches, as Exhibit 99.5, unaudited pro forma combined interim financial information of the company as of and for the six months ended June 30, 2026 and the year ended December 31, 2025. The filing states that "this Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company subsequent to the filing date of the Original Report." The merger agreement, dated September 17, 2026, involved merger subsidiaries Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC.

What Was Disclosed

Lisata Therapeutics amended its September 17, 2026 acquisition report to add audited combined financial statements of Marea Therapeutics and M2 Therapeutics prepared by Ernst & Young LLP, unaudited interim combined financials, and unaudited pro forma combined financial information, all incorporated by reference through new exhibits.